Shan Sumeera’s Post

New Healthcare Trend Report 💡 The Antibody-Drug Conjugate (ADC) market is projected to reach $44 billion by 2029. Increased M&A activity, clinical trial expansion, and a focus on precision medicine are driving this exciting sector. Watch our latest video from Tennyson Young to learn why this sector is attracting major investment. Check out the full report here: https://bit.ly/40fCogO #ExpertNetwork #HealthcareInvestment #PrivateEquity #PrivateEquityInvestment

A new study demonstrated that Extended-release buprenorphine (XR-Bup) was associated with a reduction in ED use six months after initiation, indicating a potential increase in patient adherence and a reduction in healthcare system costs overall (https://lnkd.in/e5XpSMnZ). Incremental or sustaining drug innovations like XR-Bup can disrupt the market and create enormous value for stakeholders. Ideas don't always have to be disruptive to create impact. Whether you have an idea for an incremental or a disruptive innovation, our program can help you identify how to move it into the market. Apply today - https://lnkd.in/e9FiW56p

🟢 AGENDA | Cracking the MedTech Market Access code. Discover some of the keys to success in entering the MedTech market #LessonsAccessCode 🔑 Despite developing a product that represents significant improvements for the healthcare system and the population as a whole or solves unsolved needs in the market, successful commercialisation is a complex challenge that requires resources and a meticulous strategy. Discover the market access strategies for new products, both in public and private health services, at national and international level. Don't miss this opportunity to learn the essential due diligence steps that need attention to achieve commercial success in MedTech. Moderator: . Jordi Martorell, CEO of Aortyx and chair of the CataloniaBio & HealthTech Internal Business Development Committee Speakers: . Jaume Clariana, IVD Division Director, Palex . Anna Cortina, QA & RA and Research Director, Avinent . Raquel Egea, General Director, Alma Medical Imaging . Joaquin Gonzalez, Chief Business Development Officer, BioSystems ℹ️ https://tuit.cat/LbWA1 🗓️ 21 Feb, 16-18h 📍 @PCB_UB #medtech #market #MarketAccess #health #healthcare #healthcareMarket

If you are passionate about empowering global life sciences to accelerate better health outcomes for all, follow our LinkedIn page! We will be sharing our learnings from our discussions with top 10 pharma, the latest on Global Digital Health Innovation and therapeutic area specific use cases, helping to accelerate better health outcomes across industry. If you have any questions get in touch! #Evinova #digitalsolutions #clinicaltrials #clinicaltrailresearch   

We are here to empower human centered innovations with science & smart decision making to redefine whats possible in clinical research. Follow updates to learn the Evinova journey

Vyoo Agency with two new posters HTA256, viewable on board 4039. Interested in analyzing a specific topic related to CEESP opinions, we have the database to support you. #JulieChevalier #LeaVacherot #StephaneRoze #BertrandTehard HTA 256 makes a specific focus on health economic assessments for early-stage cancer’s therapies. Less major reservation and uncertainty than the average. It shows how much expertise increased and that Pharma company now succeed more to fulfill HAS requirements.

As APACMed looks forward to creating impact on the MedTech industry in the decades to come, we continually look for opportunities that aid in the advancement of MedTech. Lance Little, Roche Diagnostics Asia Pacific, shares a critical insight on how to unlock the full potential of MedTech to further strengthen healthcare systems in this snippet from “A Decade of Progress - Looking Forward.” What do you think is the key to unlocking the next level of growth in MedTech for the Asia Pacific region?  #ADecadeofProgress is a celebration of APACMed's 10 years of continued commitment to making progress in promoting innovation and advocating for policies that advance healthcare access in the Asia Pacific. We are excited to share with you the progress we have made and the impact we look forward to making in our three-part video series, A Decade of Progress.  Watch the final instalment of our series, 𝗔 𝗗𝗲𝗰𝗮𝗱𝗲 𝗼𝗳 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 - 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗙𝗼𝗿𝘄𝗮𝗿𝗱, to understand the challenges and opportunities that will arise in the MedTech industry: https://lnkd.in/gBdeZA7B

🌟 Perfect conclusion for Day 2 of the MedTech Summit 2024 in Chicago's Safety and Compliance Track! The engaging roundtable discussion on “Analyzing the Validity for RWE Support to Clinical and Post Market Evaluations” led by Nicole Wydeven, PhD, Sr. Manager of Post Market Clinical Strategy, provided valuable insights into the pivotal role of real-world evidence (RWE) in healthcare. This session marked an impactful finale, highlighting the importance of data-driven approaches in clinical and post-market evaluations. Let's continue driving innovation with evidence-based strategies! 🚀 #MedTechSummit #WhySummits #SafetyAndCompliance #RWE #HealthcareInnovation

Innovation is a continual journey to advance the needs of patients today and of future generations. https://lnkd.in/dZBJaiSg This is a NO COST Conference #GLOBALMATCH #Switzerland #Pharmaceuticalindustry

Take Your Practice to New Heights 🚀 : Discover the Latest in #Pharmacotherapy! Delve into groundbreaking developments in drug innovation, progressive therapies, and leading-edge research that is molding the pharmacotherapy field. Acquire valuable insights into critical updates on disease states, emerging trends, and pressing issues directly influencing your practice. Seize the chance to engage in this transformative pharmacotherapy experience. Secure your spot today and become a trailblazer in the future of healthcare! https://bit.ly/48hyKTG